Literature DB >> 11511828

Increasing prevalence of non-clade B HIV-1 strains in heterosexual men and women, as monitored by analysis of reverse transcriptase and protease sequences.

C Balotta1, G Facchi, M Violin, S Van Dooren, A Cozzi-Lepri, F Forbici, A Bertoli, C Riva, D Senese, P Caramello, G Carnevale, G Rizzardini, L Cremonini, L Monno, G Rezza, C F Perno, G Ippolito, A d'Arminio-Monforte, A M Vandamme, M Moroni.   

Abstract

OBJECTIVE: We evaluated the prevalence of HIV-1 non-clade B over time in a formerly clade B-restricted area. Protease and reverse transcriptase regions of the pol gene were used for phylogenetic and recombination analysis and for clade assignment to HIV-1 A-D, F-H, J, and K strains of the M group.
METHODS: The pol gene of 349 HIV-1 patients belonging to the Italian Cohort Naive for Antiretrovirals (ICONA) were genotypically analyzed to study the prevalence of antiretroviral-associated resistance mutations. All HIV-1 pol sequences and 32 HIV reference strains were analyzed, including the reference strains for the major HIV-1 subtypes. The non-clade B sequences according to the HIV-1 Subtyping Tool program were further studied by a bootscan analysis (SimPlot) to investigate the likelihood of recombination between subtypes.
RESULTS: Phylogenetic analysis detected 19 of 349 (5.4%) non-clade B subtypes. The proportions of patients carrying non-clade B virus before and after 1997 were 1.9% and 8.4%, respectively (p =.008). Among whites, heterosexual infection and female gender were significantly associated with the presence of non-clade B subtypes (p =.001 and.005, respectively). Non-clade B HIV-1 was harbored by 14.5% of the heterosexuals who were found to be HIV-1 positive after 1997, 60% of whom were women. Bootscan analysis identified four strains as F, two as A, one as C, one as G, and 11 (57.9 %) as non-clade B recombinant subtypes.
CONCLUSION: Detection of HIV-1 subtypes and intersubtype recombinants in a previously clade B-homogeneous area indicates that the HIV-1 epidemic is evolving in Italy and that heterosexuals and women are at increased risk of infection with non-clade B HIV-1 subtypes. Sequences inferred from the pol gene yield to establish the subtype of circulating HIV-1 strains. As a consequence, genotyping of pol gene for testing resistance to antiretrovirals warrants concomitant surveillance of non-clade B subtypes.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11511828     DOI: 10.1097/00126334-200108150-00012

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  19 in total

1.  Transmission of resistant HIV type 1 variants and epidemiological chains in Italian newly diagnosed individuals.

Authors:  Alessia Lai; Michela Violin; Erika Ebranati; Marco Franzetti; Valeria Micheli; Maria Rita Gismondo; Amedeo Capetti; Paola Meraviglia; Francesco Roberto Simonetti; Giorgio Bozzi; Masimo Ciccozzi; Massimo Galli; Gianguglielmo Zehender; Claudia Balotta
Journal:  AIDS Res Hum Retroviruses       Date:  2011-11-22       Impact factor: 2.205

2.  Comparison of LCx with other current viral load assays for detecting and quantifying human immunodeficiency virus type 1 RNA in patients infected with the circulating recombinant form A/G (CRF02).

Authors:  Alessandra Amendola; Licia Bordi; Claudio Angeletti; Enrico Girardi; Giuseppe Ippolito; Maria R Capobianchi
Journal:  J Clin Microbiol       Date:  2004-02       Impact factor: 5.948

3.  Characterization of drug-resistance mutations in HIV type 1 isolates from drug-naive and ARV-treated patients in Bulgaria.

Authors:  Maria Mercedes Santoro; Massimo Ciccozzi; Claudia Alteri; Stefania Montieri; Ivailo Alexiev; Iordanka Dimova; Francesca Ceccherini-Silberstein; Danail Beshkov; Giovanni Rezza; Carlo Federico Perno
Journal:  AIDS Res Hum Retroviruses       Date:  2008-09       Impact factor: 2.205

4.  Impact of HIV-1 viral subtype on disease progression and response to antiretroviral therapy.

Authors:  Philippa J Easterbrook; Mel Smith; Jane Mullen; Siobhan O'Shea; Ian Chrystie; Annemiek de Ruiter; Iain D Tatt; Anna Maria Geretti; Mark Zuckerman
Journal:  J Int AIDS Soc       Date:  2010-02-03       Impact factor: 5.396

5.  Molecular epidemiology of HIV-1 infection in immigrant population in northern Italy.

Authors:  Caterina Sagnelli; Caterina Uberti-Foppa; Sabrina Bagaglio; Eleonora Cella; Vittoria Scolamacchia; Hamid Hasson; Stefania Salpietro; Emanuela Messina; Giulia Morsica; Silvia Angeletti; Massimo Ciccozzi; Adriano Lazzarin; Evangelista Sagnelli
Journal:  Epidemiol Infect       Date:  2020-02-05       Impact factor: 2.451

6.  TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1.

Authors:  Koen Andries; Hilde Azijn; Theo Thielemans; Donald Ludovici; Michael Kukla; Jan Heeres; Paul Janssen; Bart De Corte; Johan Vingerhoets; Rudi Pauwels; Marie-Pierre de Béthune
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

7.  TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates.

Authors:  Sandra De Meyer; Hilde Azijn; Dominique Surleraux; Dirk Jochmans; Abdellah Tahri; Rudi Pauwels; Piet Wigerinck; Marie-Pierre de Béthune
Journal:  Antimicrob Agents Chemother       Date:  2005-06       Impact factor: 5.191

8.  Transmitted drug resistance in nonsubtype B HIV-1 infection.

Authors:  Philip A Chan; Rami Kantor
Journal:  HIV Ther       Date:  2009-09-01

9.  Resistance-associated mutations to etravirine (TMC-125) in antiretroviral-naïve patients infected with non-B HIV-1 subtypes.

Authors:  Almoustapha Issiaka Maïga; Diane Descamps; Laurence Morand-Joubert; Isabelle Malet; Anne Derache; Mamadou Cisse; Victoria Koita; Alain Akonde; Bah Diarra; Marc Wirden; Anatole Tounkara; Yvan Verlinden; Christine Katlama; Dominique Costagliola; Bernard Masquelier; Vincent Calvez; Anne-Genevieve Marcelin
Journal:  Antimicrob Agents Chemother       Date:  2009-12-14       Impact factor: 5.191

10.  TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.

Authors:  Hilde Azijn; Ilse Tirry; Johan Vingerhoets; Marie-Pierre de Béthune; Guenter Kraus; Katia Boven; Dirk Jochmans; Elke Van Craenenbroeck; Gaston Picchio; Laurence T Rimsky
Journal:  Antimicrob Agents Chemother       Date:  2009-11-23       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.